The Claim
Tirzepatide reduces the risk of kidney disease progression in adults with type 2 diabetes and cardiovascular disease by 21% compared to dulaglutide, as measured by a composite endpoint of persistent macroalbuminuria, doubling of serum creatinine with eGFR <45 mL/min/1.73 m², kidney replacement therapy, or kidney-related death.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with type 2 diabetes and cardiovascular disease, tirzepatide lowers the combined risk of serious kidney outcomes—including worsening protein in the urine, significant decline in kidney function, need for dialysis, or death from kidney disease—by 21% compared to dulaglutide.
See the scientific wording
Tirzepatide reduces the risk of kidney disease progression in adults with type 2 diabetes and cardiovascular disease by 21% compared to dulaglutide, as measured by a composite endpoint of persistent macroalbuminuria, doubling of serum creatinine with eGFR <45 mL/min/1.73 m², kidney replacement therapy, or kidney-related death.
Tirzepatide helps the body use insulin better and lowers blood sugar more than dulaglutide, which reduces the extra pressure on the kidney’s filtering units, helping them last longer and work better.
What the research says
1 studyIn people with type 2 diabetes and heart disease, tirzepatide helped protect the kidneys better than dulaglutide over four years, lowering the risk of serious kidney problems like needing dialysis or losing kidney function.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.